Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-week, Randomized, Double-blind, Multi-center, Active-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of an Aliskiren-based Regimen Compared to a Lisinopril-based Regimen in Patients With Uncomplicated Severe Hypertension

NCT00219050 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-week, Randomized, Double-blind, Multi-center, Active-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of an Aliskiren-based Regimen Compared to a Lisinopril-based Regimen in Patients With Uncomplicated Severe Hypertension
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2005
Completion date
November 30, 2005
Enrollment
180
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension